Payment overview · 2025
General Payments
$70.45
4 reported records · 3 companies
Healthcare provider profile · identity verified
Shawn Dawson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OTTUMWA, IA · NPI 1306834577
Verified facts
What the public records show
CMS Open Payments records show Shawn Dawson, M.D. received $70.45 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 51.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.17 | 51.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.04 | 25.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.24 | 23.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.45 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 178 |
| Lisinopril | Lisinopril | 488 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 124 |
| Omeprazole | Omeprazole | 439 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 422 | 54 |
| Gabapentin | Gabapentin | 326 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 97 |
| Metformin Hcl | Metformin Hcl | 316 | 83 |
| Losartan Potassium | Losartan Potassium | 310 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 87 |
| Alprazolam | Alprazolam | 298 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 69 |
| Tramadol Hcl | Tramadol Hcl | 272 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 76 |
| Potassium Chloride | Potassium Chloride | 261 | 73 |
| Furosemide | Furosemide | 243 | 76 |
| Simvastatin | Simvastatin | 223 | 61 |
| Lorazepam | Lorazepam | 219 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 27 |
| Jardiance | Empagliflozin | 170 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 44 |
| Glipizide | Glipizide | 166 | 44 |
| Eliquis | Apixaban | 162 | 36 |
| Famotidine | Famotidine | 157 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 38 |
| Allopurinol | Allopurinol | 136 | 37 |
| Sertraline Hcl | Sertraline Hcl | 133 | 33 |
| Montelukast Sodium | Montelukast Sodium | 132 | 34 |
| Trazodone Hcl | Trazodone Hcl | 129 | 40 |
| Methadone Hcl | Methadone Hcl | 127 | suppressed |
| Ozempic | Semaglutide | 127 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 30 |
| Alendronate Sodium | Alendronate Sodium | 120 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 38 |
| Meloxicam | Meloxicam | 118 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 35 |
| Clonazepam | Clonazepam | 114 | 15 |
| Prednisone | Prednisone | 110 | 53 |
| Cefdinir | Cefdinir | 109 | 80 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 107 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 21 |
| Ezetimibe | Ezetimibe | 101 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 26 |
| Spironolactone | Spironolactone | 86 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 16 |
| Atenolol | Atenolol | 76 | 21 |
| Azithromycin | Azithromycin | 74 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | 23 |
| Memantine Hcl | Memantine Hcl | 73 | 15 |
| Carvedilol | Carvedilol | 71 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 17 |
| Metformin Hcl Er | Metformin Hcl | 70 | 21 |
| Bupropion Xl | Bupropion Hcl | 69 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 16 |
| Levofloxacin | Levofloxacin | 66 | 48 |
| Pregabalin | Pregabalin | 66 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 16 |
| Glimepiride | Glimepiride | 62 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 18 |
| Warfarin Sodium | Warfarin Sodium | 61 | 14 |
| Baclofen | Baclofen | 60 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 31 |
| Finasteride | Finasteride | 56 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Xtampza Er | Oxycodone Myristate | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Temazepam | Temazepam | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Rybelsus | Semaglutide | 48 | 15 |
| Amoxicillin | Amoxicillin | 47 | 33 |
| Mupirocin | Mupirocin | 46 | 27 |
| Ondansetron Odt | Ondansetron | 44 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Cephalexin | Cephalexin | 40 | 13 |
| Enalapril Maleate | Enalapril Maleate | 39 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Levemir Flexpen | Insulin Detemir | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 24 |
| Spiriva Handihaler | Tiotropium Bromide | 30 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Topiramate | Topiramate | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 20 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Valium | Diazepam | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Ms Contin | Morphine Sulfate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.45 · 4 records | Novo Nordisk Inc | CAPVAXIVE, GARDASIL 9, Ozempic, Rybelsus, TZIELD | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error